A Real-World Study Of Zilongjin Tablets Combined With Targeted Therapy To Improve The Survival Of Patients With Non-Small Cell Lung Cancer

Objective:To evaluate whether Zilongjin tablets combined with targeted therapy can inhibit tumor progression and improve quality of life and quality of life score of tumor patients.Methods:Patients with non-small cell lung cancer who were admitted to Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University and Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine from September 16,2018 to May 30,2022 were collected.A cohort study design was used,with"whether Zilongjin tablets were taken orally for≥8 weeks"as the exposure factor.The patients who met this exposure factor were divided into the integrated Chinese and western medicine treatment cohort(exposure group):Zilongjin tablet+TKI(n=183),Patients who did not meet this exposure factor were treated with western medicine(non-exposure group):TKI only group(n=104).Overall survival,quality of life,and performance status were compared between the two cohorts.Multivariate hazard proportional regression models were used to explore the influencing factors of overall survival,quality of life and performance status.Results:A total of 287 patients with NSCLC were enrolled in this study,including 183 patients in the Zilongjin tablet+TKI group and 104 patients in the TKI group.SAS JMP pro14.0 software was used to analyze the data.P<0.05 was considered statistically significant.The baseline data of the two groups were balanced and comparable.(2)The mOS of the traditional Chinese and western medicine treatment cohort was 13 months,and the western medicine treatment cohort was12 months,P=0.0222(P<0.05),and the difference was statistically significant.The mOS of stage IV patients was 12 months in the cohort treated with traditional Chinese and western medicine,and 12 months in the cohort treated with western medicine,P=0.0074(P<0.05),and the difference was statistically significant.The mOS of non-stage IV patients was 13 months in the cohort treated with traditional Chinese medicine and western medicine,and 12 months in the cohort treated with western medicine,P=0.3972(P>0.05),and the difference was not statistically significant.The 1-and 2-year survival rates of the TCM and western medicine cohort were 65.03%(119/183)and 4.92%(9/183),respectively.The 1-and 2-year survival rates of the western medicine cohort were 45.19%(47/104)and 4.81%(5/104),respectively.There was a statistically significant difference in the first year survival rate between the traditional Chinese and western medicine cohort and the western medicine cohort(χ~2=10.666,P=0.0011,P<0.05).There was no significant difference in the second year survival rate between the traditional Chinese and Western medicine cohort and the western medicine cohort(χ~2=0.002,P=0.9667,P>0.05).(3)In terms of KPS score,the difference between the two groups after treatment was statistically significant(P<0.05).The KPS effective rate was 59.02%in the TCM and Western medicine cohort,and 22.12%in the western medicine cohort.(4)Improvement of clinical symptoms:The effective rates of action,self-care,daily activities,pain or discomfort,anxiety or depression in the traditional Chinese and western medicine cohort were 12.02%,13.11%,13.11%,27.32%,25.68%,respectively,and those in the western medicine cohort were 4.81%,2.88%,2.88%,11.54%,13.46%,respectively.Oral Zilongjin tablets combined with targeted therapy can improve the quality of life of patients.(5)Among the enrolled patients,3 had adverse reactions,2 had stomach pain and 1 had abdominal pain and diarrhea.Conclusion:Zilongjin tablets combined with targeted therapy may prolong the overall survival of EGFR mutant non-small cell lung cancer patients with qi and blood deficiency,and improve the quality of life and physical status.